Melbourne – September 21, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has signed a strategic agreement to merge with ITM Isotope Technologies Munich SE in a deal valuing ITM at US$1.65 billion upfront on a cash-free, debt-free basis, with up to US$700 million in additional contingent consideration tied to regulatory and sales milestones.
Deal structures $1.25 billion in Telix stock alongside debt assumption
Under the agreement, ITM shareholders will receive approximately US$1.25 billion in the form of 105.8 million Telix shares priced at US$11.84 per share, released as Nasdaq-listed ADRs following escrow periods of up to 15 months. Telix will additionally assume US$302 million of ITM net debt at closing, with US$96 million allocated to management equity rollover and transaction expenses. Upon completion, existing Telix shareholders will hold roughly 76.3% of the combined company, with ITM shareholders holding approximately 23.7%.
Contingent payments hinge on ITM-11 approvals through 2031
Up to US$250 million in milestone payments depend on FDA approvals for ITM-11 (177Lu-edotreotide) across three indications: US$100 million for G1-G2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) by December 31, 2027; US$100 million for G2-G3 GEP-NETs by December 31, 2030; and US$50 million for Lung NETs by December 31, 2031. A further US$450 million is tied to ITM-11 net global sales exceeding US$150 million in FY2030. ITM-11 has completed its Phase 3 COMPETE trial, with a second Phase 3 study, COMPOSE, fully enrolled and an interim analysis expected in H1 2027.
ITM's isotope business delivered 40% revenue CAGR since 2021
Founded in 2004 and headquartered in Munich, ITM is the only producer of globally scaled commercial-grade lutetium-177 and distributes to over 65 countries. The company generated US$273 million in revenue in 2025, reflecting a 40% compound annual growth rate from 2021 to 2025. ITM also holds 15-year exclusive access to Bruce Power's nuclear reactors in Canada via an agreement with Isogen for 177Lu irradiation services.
Combined entity projects pro forma 2026 revenue exceeding $1.3 billion
Management estimates unaudited pro forma 2026 revenue and income for the merged company will exceed US$1.3 billion. Telix expects the deal to support a positive EBITDA contribution starting in 2027 from manufacturing growth, cost savings and pipeline synergies. The global nuclear medicine market is forecast to reach US$41 billion by 2034.
Transaction requires shareholder approval before year-end close
The deal has been approved by Telix's Board and by shareholders holding over 90% of ITM shares as of signing. Closing is targeted for the end of FY2026, pending Telix shareholder approval under ASX Listing Rules, regulatory clearances and other customary conditions. A Notice of Meeting for an extraordinary general meeting is expected in November 2026. Morgan Stanley Australia advised Telix, while Centerview Partners advised ITM.